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Abstract

Objective To report the efficacy, patient-reported,
radiographic and safety outcomes of 4 years’ certolizumab
pegol (CZP) treatment in patients with psoriatic arthritis
(PsA).
Methods RAPID-PsA (NCT01087788) was double-blind
and placebo-controlled to Week 24, dose-blind to Week
48 and open-label (OL) to Week 216. Patients were
randomised 1:1:1 to either placebo or CZP 200 mg every
2 weeks (Q2W) or 400 mg every 4 weeks (Q4W) (following
400 mg at Weeks 0/2/4). Patients randomised to CZP
continued their assigned dose in the OL period. Patients
randomised to placebo were re-randomised to CZP 200 mg
Q2W or 400 mg Q4W (post-loading dose) at Week 16
(early escape) or after the double-blind phase. We present
observed and imputed data; missing values were imputed
using non-responder imputation (NRI) for categorical and
last observation carried forward (LOCF) for continuous
measures.
Results 409 patients were randomised; 20% (54/273) of
Week 0 patients randomised to CZP had prior anti-tumour
necrosis factor (TNF) exposure; 67% (183/273) completed
216 weeks. By Week 48, 60.4% of patients achieved
Disease Activity Index for Psoriatic Arthritis low disease
activity or remission, which was maintained; 66.3%
achieved these outcomes at Week 216 (NRI). At Weeks
48 and 216, 39.2% of patients achieved minimal disease
activity (NRI). 75% reduction in Psoriasis Area and Severity
Index responses were 65% and 52% at Weeks 48 and
216 (NRI). Total resolution rates for enthesitis, dactylitis
and nail psoriasis, at 4 years, were 71%, 81% and 65%,
respectively (LOCF). Structural damage progression was
low over 4 years’ treatment. No new safety signals were
identified after Week 96.
Conclusions CZP efficacy in treating PsA was maintained
over 4 years, in patients both with and without prior antiTNF exposure, with no new safety signals identified.

Introduction
Psoriatic arthritis (PsA) is a heterogeneous
and multifaceted chronic inflammatory
musculoskeletal disease affecting up to 30%

Key messages
What is already known about this subject?
►► Previous reports of RAPID-PsA demonstrated the

efficacy and safety of certolizumab pegol (CZP)
with two CZP dose regimens over 96 weeks for the
treatment of psoriatic arthritis (PsA) in patients with
and without prior anti-tumour necrosis factor (TNF)
exposure.

What does this study add?
►► CZP efficacy in patients with and without prior

anti-TNF exposure and improvements in patientreported outcomes, psoriasis, nail disease,
enthesitis and dactylitis were maintained over 4
years’ treatment.
►► Patients completing 4 years’ CZP treatment
achieved stringent treatment targets: 44% achieved
Disease Activity Index for Psoriatic Arthritis (DAPSA)
remission, 32% achieved DAPSA low disease
activity, 58% achieved minimal disease activity and
29% achieved very low disease activity.
►► There was little radiographically detectable
progression in structural joint damage in
patients with PsA treated with CZP throughout the
4-year RAPID-PsA trial.

How might this impact on clinical practice?
►► The long-term efficacy of CZP in patients with

and without prior anti-TNF exposure and the
sustained improvements across most PsA disease
domains support the use of CZP for the long-term
therapeutic management of PsA.

of patients with psoriasis.1 2 More than half
of patients with PsA have a progressive and
erosive disease, which results in functional
impairment.3 4 In addition to peripheral joint
involvement, patients are also affected by skin
and nail psoriasis, enthesitis and dactylitis.
Moreover, PsA is associated with numerous
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extra-articular immune-mediated symptoms, such as
uveitis and inflammatory bowel disease, and comorbidities, including cardiovascular disease, obesity, diabetes,
osteoporosis, cancer, fatty liver disease, anxiety and
depression. The Group for Research and Assessment of
Psoriasis and Psoriatic Arthritis (GRAPPA) international
guidelines for the treatment of PsA have outlined how
an integrated treatment approach should be taken to
address the different clinical domains of PsA (peripheral arthritis, axial disease, enthesitis, dactylitis and nail
disease) and comorbidities.5
Previous reports of RAPID-PsA (NCT01087788), a
phase 3 double-blind, placebo-controlled trial of CZP in
patients with PsA, have demonstrated the safety and efficacy of CZP in improving multiple manifestations of the
disease, including arthritis, skin disease, nail psoriasis,
dactylitis and enthesitis, while also inhibiting progression of structural damage and providing improvements
in patient-reported outcomes (PROs)2 6; CZP efficacy was
observed from Week 12 (during the double-blind phase)
and was maintained to Week 96, in patients both with and
without prior antitumour necrosis factor (TNF) exposure.7 Here, we present the final report of long-term efficacy outcomes of CZP treatment and safety data from the
4-year RAPID-PsA trial.
Methods
Patients
Patient eligibility criteria for the RAPID-PsA trial have
been reported elsewhere.2 Briefly, eligible patients
were ≥18 years, with a diagnosis of active PsA, fulfilling
the Classification Criteria for Psoriatic Arthritis,8
of ≥6 months’ duration and had failed treatment
with ≥1 disease-modifying antirheumatic drug (DMARD).
Up to 40% of patients could have experienced loss of
efficacy (secondary failure) or intolerance to one prior
anti-TNF.
The study protocol, amendments and subject informed
consent were reviewed by a national, regional or Independent Ethics Committee or Institutional Review Board
prior to implementation. Patients’ informed consent was
obtained and documented, and the study conducted in
accordance with local regulations, International Council
for Harmonisation Good Clinical Practice requirements
and the ethical principles that have their origin in the
principles of the Declaration of Helsinki.
Study design
RAPID-PsA (NCT01087788) was a 216-week, phase 3,
randomised, multicentre study in patients with PsA.
The trial was double-blind and placebo-controlled to
Week 24, dose-blind to Week 48 and open-label (OL)
to Week 216. The primary clinical (American College of
Rheumatology (ACR) 20 at Week 12) and radiographic
(change from baseline in van der Heijde modified Total
Sharp Score (mTSS) for PsA9 at Week 24) endpoints
of RAPID-PsA and interim analyses of the dose-blind
2

period (Weeks 24–48) and the first 48 weeks of the OL
period (ie, 96 weeks from the study start) have been
reported previously.7 Here, we present data from the
combined double-blind, dose-blind and OL phase up to
Week 216.
A total of 409 patients were randomised 1:1:1 to
placebo or subcutaneous CZP 400 mg at Weeks 0, 2 and
4 (loading dose) followed by either CZP 200 mg every
2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)
(figure 1A). Patients randomised to placebo in the
dose-blind phase were re-randomised 1:1 to CZP 200 mg
Q2W or CZP 400 mg Q4W (following CZP loading dose)
either on failing to achieve ≥10% reduction in tender
and swollen joint counts at both Weeks 14 and 16 (early
escape) or after having completed the 24-week doubleblind phase (figure 1A).
Study procedures and evaluations
Efficacy assessments included ACR 20/50/70 responder
rates,10 11 Psoriasis Area and Severity Index (PASI)
75/90/100 responder rates,10 mean change from baseline in body surface area (BSA) affected by psoriasis
and ≤1% BSA responder rates (skin outcomes reported
in patients with baseline skin involvement ≥3% BSA). The
Disease Activity Index for Psoriatic Arthritis (DAPSA),12
the proportion of patients achieving DAPSA low disease
activity (LDA; DAPSA >4 and ≤14), DAPSA remission
(DAPSA ≤4), minimal disease activity (MDA; fulfilling at
least 5 of 7 MDA criteria) and very low disease activity
(VLDA; achieving all 7 MDA criteria) were also analysed.
Change in nail psoriasis, enthesitis and dactylitis were
also assessed. Enthesitis was evaluated by mean change
from baseline in the Leeds Enthesitis Index (LEI)13 and
total resolution of enthesitis (LEI=0) responder rates for
patients with baseline involvement (LEI >0). Dactylitis
was evaluated by mean change from baseline in the Leeds
Dactylitis Index (LDI)13 and total resolution (LDI=0)
responder rates for patients with baseline involvement
(defined as having at least 1 digit affected and with a
difference in circumference ≥10% compared with the
opposite digit and LDI >0). Nail psoriasis was evaluated
by mean change from baseline in the modified Nail
Psoriasis Severity Index (mNAPSI)13 and total resolution
(mNAPSI=0) responder rates for patients with baseline
involvement (mNAPSI >0).
PRO measures included pain (0–100 mm visual
analogue scale (VAS)),14 fatigue (0–10 VAS),15 function
(Health Assessment Questionnaire Disability Index,
HAQ-DI; range: 0 (mild limitations of physical function)–3 (very severe limitations of physical function)),13
the Short-Form 36-item health survey (mental component summary (MCS) and physical component summary
(PCS); standardised so that the mean and SD of each
scale in the USA general population were 50 and 10, with
higher scores indicating better health-related quality
of life)16 17 and PsA quality of life (PsAQoL; range: 0
(best)–20 (worst)).18 Improvements in these PROs were
evaluated by mean change from baseline.
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Figure 1 (A) RAPID-PsA trial design, (B) patient disposition to Week 216 and (C) Kaplan-Meier plot to time of withdrawal for
any reason, or due to lack of efficacy or adverse events, for patients randomised to CZP at Week 0. †Only 121 of the 123 Week
0 CZP 200 mg Q2W patients who completed the dose-blind period of treatment went on to start the open-label period of
treatment. ‡One fewer patient went on to start the open-label period of treatment. *Censored patients are those that withdrew
due to reasons other than lack of efficacy or adverse event and those lost to follow-up. CZP, certolizumab pegol; Q2W,
every 2 weeks; Q4W, every 4 weeks; TJC, tender joint count; SJC, swollen joint count.

Structural joint damage (measured using mTSS) was
evaluated for patients originally randomised to CZP to
Week 216 as part of the Week 216 reading campaign,
which included radiographs taken at baseline, Week
96, Week 168 and Week 216. Radiographs were also
read for patients originally randomised to placebo
who switched to CZP treatment at Week 16 or 24. For
these patients, mTSS change was assessed from CZP
initiation. Radiographic images were scored by two
central readers who were blind to patient information
and the chronological order of the images. Structural
joint damage was evaluated as mean change from baseline mTSS and the proportion of patients with no (or
minimal) structural joint damage (non-progression;
defined as change from baseline in mTSS ≤0.5 or ≤0)
to Week 216. All structural joint damage as described
above was also evaluated for patients stratified by their
baseline mTSS into two subgroups (either > or ≤ the
median baseline mTSS of 4.5).
The Safety Set consisted of patients who received at
least one dose of CZP at any point during the 216-week
trial. The occurrence of adverse events (AEs) was
assessed and recorded at every visit and coded according
to the Medical Dictionary for Regulatory Activities
(MedRA) criteria, V.14.1. Treatment-emergent adverse
events (TEAEs) occurring after the first CZP administration until 70 days after the last CZP administration were
recorded.
Statistical analysis
Efficacy results for clinical, functional and structural joint
damage outcomes are presented for patients treated
with CZP from Week 0 (both doses combined) in this
van der Heijde D, et al. RMD Open 2018;4:e000582. doi:10.1136/rmdopen-2017-000582

manuscript. Data for patients stratified by the dose they
received and data for the ‘All CZP’ group (all patients
randomised to CZP at Week 0, combined with patients
randomised to placebo at Week 0 who were later re-randomised to CZP) are presented in the online supplementary material.
Enthesitis, dactylitis and nail psoriasis measures (LEI,
LDI, mNAPSI) are reported for patients affected by the
respective symptoms at baseline. Missing categorical
data were imputed by non-responder imputation (NRI),
except for total resolution of enthesitis, dactylitis and
nail psoriasis, missing values for which were imputed by
last observation carried forward (LOCF); missing continuous data were imputed by LOCF for all patients with at
least a measurement at baseline. Observed data are also
presented.
Structural joint outcomes were evaluated using a
mixed-effect model for repeated measures (MMRM),19
with mTSS as the dependent variable, and where dose
regimen, visit and their interaction were fixed-effects.
An unstructured covariance matrix was used to account
for within-subject correlation. MMRM is a model-based
approach that was chosen because it allows the use of
all available data over the course of the study, where any
missing data are assumed to be missing at random. This is
done without having to specify a method of imputation.
Data are presented as the least squares mean with 95%
confidence intervals (CIs) for mTSS and change from
baseline in mTSS. The percentage of patients with mTSS
non-progression are reported based on the observed data
for patients assessed at each visit.
3
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Patient withdrawal due to lack of efficacy or AE was estimated using the Kaplan-Meier statistical analysis. Patients
that withdrew for other reasons and were lost to follow-up
were censored at the time of withdrawal.
Safety data are presented for the Safety Set. TEAEs are
reported as the proportion of the Safety Set who experienced each event, and in terms of event rate (ER) per 100
patient-years (PY) of exposure. Malignancies, including
lymphoma, were identified using the Standardised
MedDRA Query (SMQ), ‘Malignancies.’ ‘Infections and
Infestations’, ‘ Musculoskeletal and Connective Tissue
Disorders’ and ‘ Cardiac Disorders’ were each identified
using System Organ Classes (SOCs) of the same name.
Results
Patient disposition and baseline characteristics
There were 409 patients randomised in RAPID-PsA; 273
were randomised to receive CZP from Week 0 (baseline)
and 136 to placebo. Baseline demographic and disease

characteristics of all patients randomised to CZP have
been published previously and are summarised in online
supplementary table 1. Among patients randomised to
placebo, 59 required early escape and were re-randomised
to CZP at Week 16; 61 completed the double-blind phase
and were re-randomised to receive CZP at Week 24; 16
discontinued study treatment prior to re-randomisation
to CZP (figure 1B). Of the 393 patients who received at
least one dose of CZP at any time during the RAPID-PsA
trial, 75 (19%) had prior anti-TNF exposure, 54 (72%)
of whom were randomised to CZP at Week 0. Baseline
demographics and disease severity characteristics were
similar between all patients in the different dosing arms
as has been reported previously.7
Of the 273 patients randomised to CZP at baseline, 248 (90.8%) patients completed to Week 24, 237
(86.8%) patients completed to Week 48 and 183 (67.0%)
completed to Week 216 (figure 1B). In the combined
double-blind, dose-blind and OL periods, 36/273

Figure 2 ACR responder rates in patients receiving CZP from Week 0, stratified by prior anti-TNF exposure (A−C) and the
proportion of patients receiving CZP from Week 0 achieving MDA (fulfilling ≥5/7 MDA criteria) (D), VLDA (fulfilling 7/7 MDA
criteria) (E) and DAPSA LDA (>4 and ≤14) or remission (≤4) (F) over 4 years’ CZP treatment. Data are shown for the Randomised
Set. ACR20/50/70: 20%, 50% and 70% or greater improvement in ACR score. ACR, American College of Rheumatology; CZP,
certolizumab pegol; DAPSA, Disease Activity Index for Psoriatic Arthritis; LDA, low disease activity; LOCF, last observation
carried forward; MDA, minimal disease activity; NRI, non-responder imputation; OC, observed case; REM, remission;
TNF, tumour necrosis factor; VLDA, very low disease activity.
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Week 24
Observed
n

Baseline value
Observed
n

Week 0 CZP dose combined (n=273)

199

−
−
−
−

ACR50

  Naive*

  Experienced†

ACR70

50
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65

51.3 (60.0)

73

CFB LDI**, mean (SD)

LDI=0**
−
Patient-reported outcomes: mean (SD)

158

−

65

158

179

179

249

LEI=0¶

3.0 (1.6)

3.3 (2.0)

10.8 (8.2)

249

−

273
197

CFB swollen joint count, mean (SD)

CFB mNAPSI§, mean (SD)

20.5 (15.0)

149

149

172

273

CFB tender joint count, mean (SD)

24.2 (22.4)

144

249

249

249

249

mNAPSI=0§

−

BSA ≤1%‡

0

0.4

0

249

CFB LEI¶ , mean (SD)

166

CFB % BSA ‡, mean (SD)

144

−

PASI75‡
−

273

VLDA

−

273

MDA

PASI90‡

273

DAPSA remission

PASI100‡

144

273

DAPSA LDA

1.5

273

CFB DAPSA, mean (SD)

50

−
−

  Naive*

50

199

249

  Experienced†
44.8 (22.9)

249

−

  Experienced†

249
199

−
−

ACR20

  Naive*

65.9

73.8

−46.3 (41.3)

65.2

−1.9 (1.9)

38.5

−2.0 (2.1)

−7.8 (7.6)

−12.1 (12.8)

38.9

−17.0 (18.9)

25.7

47.9

70.8

14.9

38.2

25.3

29.7

−26.8 (20.2)

28.0

29.1

28.9

48.0

47.2

47.4

64.0

66.3

69.9

−47.3 (55.3)

64.0

−1.9 (1.8)

36.5

−1.9 (2.2)

−7.7 (7.7)

−11.6 (13.7)

35.5

−16.1 (19.5)

22.3

41.6

61.4

13.6

34.8

23.4

28.2

−25.9 (21.0)

25.9

26.5

26.4

44.4

42.9

43.2

59.3

60.3

60.1

Imputed

62

62

149

149

172

172

235

235

140

140

136

136

136

233

237

239

239

239

45

190

235

45

190

235

45

190

235

n

88.7

−46.8 (41.3)

71.1

−2.1 (1.8)

54.1

−2.3 (2.3)

−8.6 (7.4)

−13.0 (13.4)

55.7

−18.8 (20.4)

41.9

55.9

78.7

19.7

45.1

28.5

37.7

−29.4 (20.7)

40.0

38.4

38.7

57.8

55.3

55.7

73.3

77.9

77.0

Observed

Week 48

Clinical disease activity and patient-reported outcomes in patients randomised to CZP treatment at Week 0

Clinical outcomes: % patients achieving outcome, unless otherwise indicated

Table 1

80.8

−47.1 (55.0)

68.0

−2.0 (1.8)

50.8

−2.1 (2.3)

−8.5 (7.6)

−12.4 (14.2)

50.6

−17.5 (20.6)

34.3

45.8

64.5

16.8

39.2

25.6

34.8

−27.8 (21.6)

33.3

33.3

33.3

48.1

47.9

48.0

61.1

67.6

66.3

Imputed

50

50

110

110

132

132

185

185

109

109

108

108

108

183

185

185

185

185

34

151

185

34

151

185

34

151

185

n

92.0

−50.3 (39.5)

77.3

−2.4 (1.7)

71.2

−2.9 (1.9)

−9.3 (8.2)

−15.8 (13.1)

62.4

−21.0 (19.6)

43.5

62.0

79.6

29.0

57.8

44.3

31.9

−33.7 (21.5)

47.1

52.3

51.4

64.7

63.6

63.8

82.4

80.1

80.5

Observed

Week 216

Continued

80.8

−47.5 (55.4)

70.9

−2.2 (1.9)

64.5

−2.6 (2.2)

−8.8 (8.0)

−13.5 (14.8)

55.4

−18.3 (20.4)

28.3

40.4

51.8

19.4

39.2

35.9

30.4

−29.5 (23.5)

29.6

36.1

34.8

40.7

43.8

43.2

51.9

55.3

54.6

Imputed

Psoriatic arthritis

5

6
272
268

CFB PsAQoL

CFB SF-36 PCS
41.3 (12.0)

33.2 (7.7)

11.2 (5.6)

6.3 (2.1)

60.4 (19.6)

240

240

248

239

249

+4.9 (9.6)

+8.5 (9.0)

−4.1 (5.2)

−2.2 (2.5)

−29.7 (27.2)

n

+4.5 (10.0)

+8.0 (9.1)

−3.9 (5.1)

−2.0 (2.5)

−28.5 (27.2)

232

232

238

233

238

+4.4 (10.1)

+9.3 (9.1)

−4.5 (5.2)

−2.3 (2.4)

−33.6 (27.4)

−0.57 (0.59)

Observed

−0.48 (0.60) 236

Imputed

Week 48
n

+4.0 (10.1)

+8.5 (9.2)

−4.2 (5.2)

−2.2 (2.5)

−30.6 (28.3)

181

181

184

181

185

+5.4 (10.6)

+9.9 (10.3)

−5.1 (5.5)

−2.7 (2.7)

−37.4 (27.2)

−0.57 (0.63)

Observed

−0.52 (0.61) 185

Imputed

Week 216

+3.6 (11.3)

+8.8 (10.2)

−4.5 (5.7)

−2.3 (2.7)

−32.1 (29.7)

−0.50 (0.65)

Imputed

Data are shown for the Randomised Set. Data were imputed using NRI for missing categorical data, except for total resolution of enthesitis (LEI=0), dactylitis (LDI=0) and
nail psoriasis (mNAPSI=0), missing values for which were imputed by LOCF; missing continuous data were imputed by LOCF.
*Anti-TNF naive patients, n=219.
†Anti-TNF experienced patients, n=54.
‡Patients with baseline BSA ≥3%, n=166.
§Patients with mNAPSI >0 at BL, n=197.
¶Patients with LEI >0 at BL, n=172.
**Patients with LDI >0 at BL, defined as having at least 1 digit affected and with a difference in circumference ≥10% compared with the opposite digit, n=73.
ACR, American College of Rheumatology; ACR20/50/70: 20% , 50% and 70% or greater improvement in ACR score; BL, baseline; BSA, body surface area;
CFB, change from baseline; CZP, certolizumab pegol; DAPSA, Disease Activity Index for Psoriatic Arthritis; HAQ-DI, Health Assessment Questionnaire Disability Index;
LDA, low disease activity; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesitis Index; LOCF, last observation carried forward; MCS, mental component summary; MDA,
minimal disease activity; mNAPSI, modified Nail Psoriasis Severity Index; NRI, non-responder imputation; PASI75/90/100, 75%, 90% or 100% improvement in the
Psoriasis Area and Severity Index; PCS, physical component summary; PsAQoL, PsA quality of life; SF-36, Short Form 36-item health survey; TNF, tumour necrosis
factor; VLDA, very low disease activity.

268

269

CFB fatigue

CFB SF-36 MCS

273

CFB pain

−0.50 (0.59)

n

n
248

Observed

Observed
1.31 (0.63)

Week 24

Baseline value

Week 0 CZP dose combined (n=273)

273

Continued

CFB HAQ-DI

Table 1
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Figure 3 PASI responder rates (A, B) and total resolution in (C) nail psoriasis, (D) enthesitis and (E) dactylitis in affected
patients receiving CZP from Week 0, over 4 years’ treatment. Data are shown for the Randomised Set. PASI responder rates
are given for patients with baseline skin involvement (≥3% body surface area affected by psoriasis). Total resolution rates for
nail psoriasis, enthesitis and dactylitis are presented for patients affected by the respective conditions at baseline, respectively
defined as modified Nail Psoriasis Severity Index >0 for nail psoriasis; Leeds Enthesitis Index >0 for enthesitis and Leeds
Dactylitis Index >0, defined as having at least 1 digit affected and with a difference in circumference ≥10% compared with the
opposite digit, for dactylitis. CZP, certolizumab pegol; LOCF, last observation carried forward; NRI, non-responder imputation;
OC, observed case; PASI, Psoriasis Area and Severity Index.

(13.2%) and 9/273 (3.3%) patients withdrew from the
study due to an AE or lack of efficacy, respectively; 45/273
(16.5%) withdrew for other reasons (figure 1C).
Efficacy outcomes
The significant improvements seen in joint disease in
patients with PsA, as measured by ACR 20/50/70 after
24 weeks of CZP treatment, were generally maintained
throughout the dose-blind and OL phases of the 4-year
study and were similar irrespective of prior anti-TNF
exposure (online supplementary figure 1, figure 2A–C
and table 1).
Improvements in disease activity in patients initially
randomised to CZP, assessed by evaluating the number
of patients achieving MDA and VLDA (which include
joint and skin disease components and PROs20) and the
patients’ DAPSA (a disease activity index based on peripheral joint disease, global activity, pain, and CRP levels12),
were maintained from Week 24 to Week 216 (table 1 and
figure 2). Of patients completing 4 years’ CZP treatment,
29% achieved VLDA, more than half achieved MDA and
more than 75% achieved either DAPSA remission or
DAPSA LDA (table 1 and figure 2D–F).
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Among patients with skin involvement (≥3% BSA)
at baseline, improvements in psoriasis were generally maintained from the end of the double-blind
phase at Week 24 to Week 216, with more than half
achieving 75% reduction in PASI and BSA ≤1% at
4 years (figure 3A–B and table 1). Improvements in
psoriasis were also similar in patients with and without
prior anti-TNF exposure (online supplementary figure
2D and online supplementary figure 3D). As expected,
greater PASI75 and PASI100 responder rates were
observed and sustained in patients with more severe
skin involvement at baseline (PASI ≥10 vs PASI <10;
online supplementary figure 2E and online supplementary figure 3E).
For patients with enthesitis, dactylitis or nail psoriasis
at baseline, previously reported improvements achieved
by Week 24 in LEI, LDI and mNAPSI, respectively, were
maintained to Week 216 (table 1). More than two-thirds
of patients treated with CZP, with baseline involvement of
dactylitis, enthesitis and nail psoriasis, went on to achieve
total resolution of their respective conditions over 4 years
(table 1 and figure 3C–E).
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Table 2 Structural joint damage in patients randomised to
CZP treatment at Week 0
(A) Change in mTSS from baseline to Week 216
Week 0 CZP dose
combined (n=273)
mTSS at baseline
Observed case (n=269)
 Mean (SD)

16.03 (34.67)

 Median

4.50

 (Min, max)

(0, 342.5)

MMRM estimates, least squares (LS) mean (SE), 95% CI
mTSS at baseline

15.96 (2.24), 11.55 to 20.36

 CFB at Week 96

0.28 (0.12), 0.04 to 0.51

 CFB at Week 168
 CFB at Week 216

0.62 (0.19), 0.25 to 0.99
0.72 (0.20), 0.33 to 1.11

(B) Observed rate of structural joint damage nonprogression at Weeks 96 and 216
Observed case

Week 0 CZP dose
combined (n=273)

Time point

Week 96

Week 216

Assessed for progression, n
Rate of non-progression
(CFB in mTSS ≤0.5), n (%)*
Rate of non-progression
(CFB in mTSS ≤0), n (%)*

214

186

180 (84.1)

145 (78.0)

157 (73.4)

121 (65.1)

Data are shown for the Randomised Set.
*Percentage is based on the number of participants assessed for
progression at the visit.
CFB, change from baseline; CZP, certolizumab pegol; LS, least
squares; MMRM, mixed-effect model for repeated measures;
mTSS, modified Total Sharp Score.

Radiographic assessments showed minimal structural joint damage progression in patients treated with
CZP from Week 0 to Week 216 (table 2) and in patients
originally randomised to placebo, who were re-randomised to CZP at Week 16 or 24 (online supplementary table 5). Patients with baseline mTSS greater than
the median baseline score (with more severe disease
than those with a baseline mTSS less than the median)
also had slightly higher levels of change in mTSS from
baseline to Week 216, though progression in structural joint damage remained low in both subgroups
(online supplementary table 6).
For all measured PROs – HAQ-DI, pain, fatigue,
PsAQoL, SF-36 PCS and SF-36 MCS – early improvements observed at Week 24 were generally maintained
or further improved at Week 216 (table 1). The most
notable improvement was in pain, which improved by
more than 50% by Week 216.
Improvements in the signs and symptoms of PsA in
patients treated with CZP over 4 years, by all measures
evaluated in this study, were similar irrespective of CZP
dose regimen, and when patients randomised to CZP
8

at Week 0 were evaluated together with patients re-randomised from placebo to CZP at Week 16 or 24 (online
supplementary figures 1–3 and online supplementary
tables 2–6).
Safety
Total exposure to CZP in RAPID-PsA was 1320.8 PY.
TEAEs occurred in 367 patients (93.4%, ER=257.9 per
100 PY), the majority of which were mild or moderate.
Severe TEAEs as classified by the investigator were
reported in 71 patients (18.1%). Serious TEAEs occurred
in 100 patients (25.4%, ER=11.9 per 100 PY), and in 27
cases (6.9%), this led to permanent withdrawal. The most
common serious TEAEs reported were in the ‘Infections
and Infestations’, and ‘Musculoskeletal and Connective
Tissue Disorders’ SOCs (table 3). The safety profile of
CZP was similar for both dosing regimens.
Of the 23 infections considered to be serious, the most
common was pneumonia, with four cases reported; there
were no confirmed cases of active tuberculosis. Fiftyfour (13.7%) patients experienced a TEAE leading to
withdrawal from the study. During the study, a total of
10 patients (2.5%) had a serious cardiac disorder and 7
patients (1.8%) had a malignancy table 3. There were 3
reports of breast cancer and single reports of lymphoma,
metastatic gastrointestinal cancer, ovarian cancer and
cervix carcinoma stage 0. No cases of uveitis or suicidality
were reported as TEAEs in this study.
Six deaths occurred during the study, two in the
double-blind period, one in the dose-blind period and
three in the OL period between 48 and 96 weeks, which
have all been reported previously (two cardiac disorders, one sudden death, one infection, one case each of
breast cancer and lymphoma).7 No further deaths were
reported, and no new safety signal was identified from
Week 96 to Week 216.
Discussion
Two-thirds of the patients originally randomised to CZP
in the RAPID-PsA trial completed the 4-year study. CZP
demonstrated long-term efficacy in achieving improvement in disease activity in most of the major disease
domains of PsA; for most patients completing the trial,
CZP treatment demonstrated sustained efficacy in
improving joint disease, skin and nail psoriasis, enthesitis
and dactylitis, by all disease activity and PRO measures
assessed, which was similar with both 200 mg Q2W and
400 mg Q4W dose regimens. The study has shown CZP to
have a safety profile that is expected for this therapeutic
class, with the most frequent serious TEAEs being infections; no new safety signals have been identified since
the Week 96 report of RAPID-PsA.7
More than 7 in every 10 patients with PsA completing
4 years' CZP treatment (and 6/10 of the intention-totreat population) achieved DAPSA remission or DAPSA
LDA, which relate to improvements in peripheral joint
disease and patient reported outcomes. An international
van der Heijde D, et al. RMD Open 2018;4:e000582. doi:10.1136/rmdopen-2017-000582
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Table 3 Treatment-emergent adverse events for all patients treated with CZP during the combined double-blind, dose-blind
and open-label periods of RAPID-PsA
All CZP* 200 mg
Q2W (n=198)

All CZP* 400 mg
Q4W (n=195)

All CZP* dose
combined (n=393)

Exposure to CZP (medication duration, patient-years)

674.4

646.4

1320.8

Any TEAE

184 (92.9) (266.6)

183 (93.8) (248.7)

367 (93.4) (257.9)

 Mild, n (%)

169 (85.4)

167 (85.6)

336 (85.5)

 Moderate, n (%)

132 (66.7)

129 (66.2)

261 (66.4)

 Severe, n (%)

37 (18.7)

34 (17.4)

71 (18.1)

 Infections and infestations

13 (6.6) (2.4)

10 (5.1) (2.2)

23 (5.9) (2.3)

 Musculoskeletal and connective tissue disorders

9 (4.5) (1.3)

8 (4.1) (2.0)

17 (4.3) (1.7)

 Serious cardiac disorders†

8 (4.0) (1.2)

2 (1.0) (0.3)

10 (2.5) (0.8)

 Malignancies‡

3 (1.5) (0.6)

4 (2.1) (0.6)

7 (1.8) (0.6)

Withdrawals due to TEAEs, n (%)

27 (13.6)

27 (13.8)

54 (13.7)

Serious TEAEs

49 (24.7) (11.7)

51 (26.2) (12.1)

100 (25.4) (11.9)

Withdrawals due to serious TEAEs, n (%)
Deaths§ , n (%)

13 (6.6)
3 (1.5)

14 (7.2)
3 (1.5)

27 (6.9)
6 (1.5)

n (%) (ER), unless otherwise stated

Most common serious TEAEs

Other adverse events of interest

Data are shown for the Safety Set during the combined double-blind, dose-blind and open-label periods of RAPID-PsA.
*Includes all patients exposed to ≥1 dose of CZP (including patients randomised to placebo re-randomised to CZP).
† Serious cardiac disorders reported are serious TEAEs within the ‘Cardiac Disorders’ system organ class.
‡ Malignancies, including lymphoma, were identified using the Standardised MedDRA Query, ‘malignancies.’
§ Deaths due to cardiac disorders or infection may have been associated with more than one event.
CZP, certolizumab pegol; ER, event rate per 100 patient-years; Q2W, every 2 weeks; Q4W, every 4 weeks; TEAE, treatment-emergent
adverse event.

taskforce of physicians and patients recently developed
recommendations for treatment targets in PsA; they
acknowledged that DAPSA remission may be difficult to
achieve in patients with long-standing disease, for whom
they recommend MDA be used as a treatment target.21
Almost 60% of patients completing 4 years’ CZP treatment had achieved MDA (≥5/7 MDA criteria), and half
of those also achieved the most stringent target of VLDA
(7/7 MDA criteria) indicating that CZP can deliver
low disease activity with respect to articular disease,
skin disease, pain, function and PROs, for a substantial
proportion of patients.
There is overlap between the DAPSA and MDA/
VLDA treatment targets; however, the latter also includes
the domain of skin disease. There are diverse opinions
regarding whether it is better to assess skin separately
(in addition to the DAPSA) or as part of the composite
outcome (such as the MDA/VLDA).22 Psoriasis is a cause
of frustration and embarrassment in many patients with
PsA that adds substantially to their burden of disease
and lessens their quality of life.23 24 CZP demonstrated
sustained efficacy in improving psoriatic skin disease,
with more than half of the intention-to-treat population
in RAPID-PsA with BSA ≥3% at baseline having achieved
BSA ≤1% at Week 216.
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Nail psoriasis, dactylitis and enthesitis also contribute
significantly to the impact of disease on patients’ quality
of life.25 RAPID-PsA has demonstrated the sustained,
long-term efficacy of CZP in improving these symptoms
of PsA, with more than 6 in every 10 patients with baseline involvement achieving total resolution of nail psoriasis, dactylitis and enthesitis.
PROs are important components in the evaluation of
disease impact and therapy response in patients with
PsA. The current study showed that patients treated with
CZP reported improvements for all PROs measured.
The largest improvement was in pain, which improved
by more than 50%. Structural joint damage in PsA has
been associated with disease activity and severity26 and
often correlates with functional impairment.4 There
was minimal progression of structural joint damage in
patients with PsA treated with CZP, as measured by mTSS,
throughout the 4 years of the RAPID-PsA trial, even in
patients with more severe structural joint damage at baseline. The Week 216 radiographic results indicated that
the proportion of patients treated with CZP over 4 years
with structural joint damage non-progression from CZP
baseline remained high. Except for CZP and golimumab,
such long-term structural joint damage progression data
have not been reported for other anti-TNFs or other
biological DMARDs (targeting interleukin-12/17/23)
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and targeted synthetic DMARDs (phosphodiesterase type
4 inhibitors) approved for the treatment of PsA. Notably,
the MMRM analysis used in this study to estimate radiographic progression assumed that the mTSS of patients
who withdrew from the study would have been statistically
similar to other patients receiving the same dose regimen
and who had a similar observed mTSS at baseline, had
they remained in the study—an assumption that cannot
be verified based on the available data.
In patients who do not respond adequately to their first
biological DMARD, the GRAPPA and European League
Against Rheumatism treatment guidelines for PsA both
recommend switching to a second biological DMARD;
including the option to switch between anti-TNFs.5 21 A
head-to-head trial of CZP and the anti-TNF adalimumab
in patients with rheumatoid arthritis recently demonstrated the efficacy and safety of switching to a second
anti-TNF after primary failure to an initial anti-TNF.27
In this study of CZP in patients with PsA, although
only around 1 in 5 had previously been treated with an
anti-TNF, the efficacy of CZP was similar in patients both
with and without prior anti-TNF exposure, indicating
that CZP may be effective in patients who do not respond
adequately to their first biological DMARD.
The limitations of the RAPID-PsA study include the
lack of a placebo control beyond Week 24 and inherent
bias in having dose-blind and OL periods, when the
patient is aware that they are receiving active treatment,
as is their physician. As is true for all clinical trials,
patient withdrawal from the study also introduces a risk
of bias in the data, and the impact of patient withdrawal
is likely to be greater in a long-term study. Imputation
of the missing data that results from patient withdrawal
helps to conserve the validity of the analyses, but also
requires assumptions to be made about the measurements that patients would have had if they had remained
in the study. Here, we have reported both observed and
imputed data to minimise the risk of bias. Another limitation of clinical trials is that while the long-term clinical
efficacy and safety data are relevant to clinical practice,
the study participants are not completely representative
of all patients treated in the clinical practice. In conclusion, the 4-year data demonstrating the efficacy of CZP
across most PsA disease domains in the RAPID-PsA study
support CZP treatment for the long-term therapeutic
management of PsA.
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